Mablink Bioscience
Mablink Bioscience is an antibody-drug Conjugates founded in 2018.
3
Funding Rounds
$39.6m
Money raised
Overview
Mablink Bioscience is an antibody-drug Conjugates founded in 2018.
- Website:
- Business model: B2B
- Headquarters: Lyon
- Social accounts: linkedin
Funding
Funding series
Funding Series Analysis
The company Mablink Bioscience has raised a total of $39.6m in funding over 3 rounds.
Key Insights:
- Mablink Bioscience October 2022 Series A Funding Round: $30m
- Mablink Bioscience Seed round, April 2021: $4.8m
- Mablink Bioscience April 2021 Seed Funding Round: $4.8m
Mablink Bioscience October 2022 Series A Funding Round
$30m
Mablink Bioscience Seed round, April 2021
$4.8m
Mablink Bioscience April 2021 Seed Funding Round
$4.8m
Industries
Mablink Bioscience is active in the following industries: